Cardiol Therapeutics Inc. (NASDAQ : CRDL) Stock

Innovative Pipeline Cardiol Therapeutics (CRDL) is a late-stage life sciences company at the forefront of developing cutting-edge anti-inflammatory and anti-fibrotic therapies for heart disease, with a focus on addressing significant unmet medical needs in recurrent pericarditis and heart failure.

Lead candidate, CardiolRx™ The company's lead drug, CardiolRx™, targets critical pathways in heart disease, specifically modulating inflammasome activation, which plays a vital role in inflammation and fibrosis associated with various cardiac conditions.

A validated, blockbuster-scale market Recurrent pericarditis has emerged as a highly attractive commercial market. The only FDA-approved therapy for recurrent pericarditis has achieved impressive commercial adoption, despite it being an injectable immunosuppressive biologic associated with increased infection risk. This biologic is expected to generate >$950 million in revenue in 2026, demonstrating both substantial unmet patient need and the significant value assigned to effective therapies in this underserved cardiovascular indication.

CardiolRx™ targets a >$1 billion opportunity CardiolRx™ is positioned to enter the high-value recurrent pericarditis market where rapid adoption of the first approved therapy has already demonstrated blockbuster-scale commercial potential. Company-cited third-party estimates indicate more than $1 billion in peak sales potential in recurrent pericarditis alone, highlighting the magnitude of the opportunity and the potential for CardiolRx™ to become a major commercial and valuation driver.

Competitive advantage With FDA Orphan Drug Designation granted for pericarditis, which includes recurrent pericarditis, CardiolRx™ benefits from a favorable regulatory pathway while also enhancing its development profile and providing potential market exclusivity upon approval.

A pivotal Phase III catalyst is approaching The MAVERIC Phase III trial is designed to support a potential U.S. NDA for CardiolRx™ in recurrent pericarditis and represents Cardiol’s most important near-term value inflection point. With enrollment >75% complete, topline results anticipated in Q1 2027, and a cash runway into Q4 2027 – MAVERIC is positioned as a transformational catalyst.

Positive Phase II results The pivotal MAVERIC Phase III program is meaningfully de-risked by successful Phase II proof-of-concept data in recurrent pericarditis, as well as supportive Phase II clinical evidence in myocarditis, reinforcing CardiolRx™’s anti-inflammatory potential across related inflammatory heart diseases.

Led by elite pericarditis expertise MAVERIC is guided by a world-class group of pericarditis and cardiovascular inflammation leaders who were involved in the design of the pivotal trial that led to FDA approval of the only therapy for recurrent pericarditis. The MAVERIC program involves leading centers and investigators from institutions including Cleveland Clinic, Mayo Clinic, Northwestern, Massachusetts General Hospital, Columbia/NewYork-Presbyterian, NYU Langone, and others. This depth of clinical leadership highlights the importance and strengthens the execution quality of the program.

A differentiated product profile versus injectable biologics CardiolRx™ is an oral, pharmaceutically manufactured small-molecule therapy with a non-immunosuppressive profile and the potential to offer a more accessible treatment option for patients. Phase II MAVERIC data showed rapid and durable reductions in pericarditis pain, reductions in inflammation, and fewer recurrence episodes. This profile compares favorably with costly injectable biologics, which are associated with immunosuppression, injection burden, dependency, and high recurrence risk after discontinuation.

Strong scientific rationale with broader pipeline leverage CardiolRx™ is designed to target inflammatory and pro-fibrotic pathways implicated in recurrent pericarditis and other inflammatory heart diseases, including modulation of the NLRP3 inflammasome pathway. The same scientific foundation supports broader pipeline opportunities, including acute myocarditis and CRD-38 for heart failure, providing more than a single-asset story and positioning Cardiol across a larger inflammatory heart disease platform.